BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, January 13, 2025
See today's BioWorld
Home
» Medarex, BMS MDX-010 Deal: Payments Could Total $530M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Medarex, BMS MDX-010 Deal: Payments Could Total $530M
Nov. 9, 2004
By
Aaron Lorenzo
No Comments
Medarex Inc. could receive up to $530 million through a deal to partner a Phase III metastatic melanoma product with Bristol-Myers Squibb Co. (BioWorld Today)
BioWorld
